Recent Progress on Lipid Intake and Chronic Kidney Disease

Pei, Ke; Gui, Ting; Li, Chao; Zhang, Qian; Feng, Huichao; Li, Yunlun; Wu, Jibiao; Gai, Zhibo

Abstract: The incidence of chronic kidney disease (CKD) is associated with major abnormalities in circulating lipoproteins and renal lipid metabolism. This article elaborates on the mechanisms of CKD and lipid uptake abnormalities. The viewpoint we supported is that lipid abnormalities directly cause CKD, resulting in forming a vicious cycle. On the theoretical and experiment fronts, this inference has been verified by elaborately elucidating the role of lipid intake and accumulation as well as their influences on CKD. Taken together, these findings suggest that further understanding of lipid metabolism in CKD may lead to novel therapeutic approaches.

DOI: https://doi.org/10.1155/2020/3680397

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-200018
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:
Pei, Ke; Gui, Ting; Li, Chao; Zhang, Qian; Feng, Huichao; Li, Yunlun; Wu, Jibiao; Gai, Zhibo (2020). Recent Progress on Lipid Intake and Chronic Kidney Disease. BioMed Research International, 2020:3680397. DOI: https://doi.org/10.1155/2020/3680397
Recent Progress on Lipid Intake and Chronic Kidney Disease

Ke Pei, Ting Gui, Chao Li, Qian Zhang, Huichao Feng, Yunlun Li, Jibiao Wu, and Zhibo Gai

1College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
2Key Laboratory of Traditional Chinese Medicine for Classical Theory, Ministry of Education, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
3First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
4Acupuncture and Massage College, Shandong University of Traditional Chinese Medicine, Jinan 250355, China
5The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China
6Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, University of Zurich, 8006 Zurich, Switzerland

Correspondence should be addressed to Yunlun Li; yunlun.lee@hotmail.com, Jibiao Wu; wujibiao1963@163.com, and Zhibo Gai; gaizhibo@gmail.com

Received 1 November 2019; Revised 12 February 2020; Accepted 18 February 2020; Published 25 April 2020

1. Introduction

Lipids contain many molecules that contribute to structural components of membranes and signal transduction that regulates a variety of cellular events to maintain physiological homeostasis. Recent research on the relationship between lipid disorders and kidney disease concluded that when the balance of lipid uptake, synthesis, and excretion in the kidney is disrupted, lipid accumulation occurs and causes nephrotoxicity and chronic kidney disease (CKD) [1]. Chronic kidney disease represents a serious public health problem due to its increased morbidity and prevalence worldwide. Dyslipidemia is frequently found in every stage of CKD, and lipid disorders aggravate the progression of CKD. In fact, dyslipidemia leads to impairment of the glomerular filtration barrier and proteinuria. The increase in serum triglyceride to high-density lipoprotein (HDL) ratio is a characteristic of dyslipidemia in CKD patients and is also an independent indicator of disease progression. Several clinical studies have confirmed that an elevated serum triglyceride to HDL ratio has a major impact on the decrease of the estimated glomerular filtration rate (eGFR) and the development of CKD [2]. Dyslipidemia itself is not enough to cause kidney injury; however, it is one of the necessary components of the multistep mechanisms since it also induces inflammation, oxidative stress, and lipotoxicity [1]. CKD also leads to marked alterations of secondary abnormalities in lipid metabolism [3]. Several studies have documented that CKD leads to decreased fatty acid oxidation (FAO), which could be an additional mechanism resulting in lipid accumulation [4]. An increased abundance of saturated C16 or C20 free fatty acids (FFAs) accompanied by impaired β-oxidation has been noted in the late stage of CKD, contributing to further accumulation of saturated fatty acids (SFA) and leading to cell dysfunction, cell death, and the further progression of CKD [5]. Nowadays, most studies emphasize the impact of lipid metabolism disorders in chronic kidney disease (CKD). Less attention has been paid to the lipid intake of patients with CKD and the
possibility of using this as a tool to improve CKD. In conclusion, this article focuses on the mechanism of lipid intake leading to CKD and possible therapeutic approaches.

2. High-Fat Diet Intake and CKD

A high-energy, high-fat diet (HFD), especially one with a high-SFA intake, promotes obesity and metabolic syndrome abnormalities [6–10]. The excessive intake of energy, including a HFD, causes an imbalance between renal lipogenesis and lipolysis, which is considered to be an initial reason for renal lipid accumulation, and eventually renal injury [11]. After evaluating the population-based dietary pattern with the risk of incident CKD in a 6.1-year follow-up, it turned out that a high-fat, high-sugar diet was associated with an observable increase in the occurrence (46%) of incident CKD, whereas a lactovegetarian diet might be protective against the incidence of CKD by 43% [12]. Western diet patterns characterized by red and processed meat, saturated fat, and sweets were positively associated with a decrease in renal function after 11 years of follow-up in the participants from the Nurses’ Health Study (NHS). Furthermore, participants who were in the highest third of the high-fat, high-sugar dietary pattern had a 49% increased rate of developing CKD, independent of diabetes and hypertension [13]. These studies show that dietary intake is a vital modifiable risk factor that is associated with delaying or preventing the development of CKD in humans [14–16]. However, there were also clinical studies showing a reverse association of body mass index (BMI) and survival in patients with advanced chronic kidney disease (CKD) as compared to the general population [17, 18]. Adequate management with respect to the specific role of obesity in different stages of CKD should be further integrated in routine renal care [19].

3. Lipid Uptake in the Kidney

Renal cells take up lipoproteins by scavenger receptors (SRs), including SR-B (CD36), SR-A, and SR-E (LOX-1). Under pathogenic stimulation, the scavenger receptors are dysregulated and their level is positively associated with the level of renal injury [20]. Furthermore, the expression of scavenger receptors (SRs) is not downregulated by intracellular cholesterol. As a result, cells expressing SRs can internalize a mass of cholesterol esters, leading to foam cell formation. All of these mechanisms result in the excessive absorption of lipids by kidney cells [1].

3.1. CD36-Mediated Lipid Uptake. CD36 is expressed on various cell types, such as monocytes, macrophages [21], and proximal tubular cells (PTCs) [22], and mediates phagocytosis and degradation of oxidized low-density lipoprotein (ox-LDL) [23]. CD36 is also one of the most important transporters and transmembrane glycoproteins with a high-affinity uptake of long-chain fatty acid (LCFA, as schematically shown in Figure 1) [24–29]. Its level is positively correlated with the degree of renal injury if pathogenic stimuli, such as aminonucleoside (PA), have been applied [20]. Most nonesterified fatty acids (NEFAs) in the blood are combined with carrier proteins (mostly albumin), and their uptake requires dissociation from carrier proteins mediated by CD36 [30]. Albumin-bound fatty acids are extracted from filtrate by albumin endocytosis mediated by CD36 or by a receptor in the proximal renal tubules [31]. Although the filtration barrier prevents exposure of the proximal tubules to large lipoproteins, in individuals with proteinuria nephropathy including diabetic kidney disease (DKD), the proximal tubular cells are exposed to high amounts of filtered albumin and NEFAs. The excessive accumulation of nonesterified FFAs and triglycerides in the kidney leads to cytotoxicity, contributing to CKD progression [32]. The role of CD36 in the kidney has been investigated extensively [33]. SFA, which increase CD36 expression in podocytes, are major ligands for CD36, resulting in enhancement of FFA uptake, which will contribute to the generation of the vicious cycle [34]. Recently, the transgenic overexpression of CD36 in the kidneys of mice has been shown to induce lipid accumulation in the kidney [35]. It has been verified that CD36 increased podocyte apoptosis in primary nephrotic syndrome [36]. Saturated FFAs induce podocyte apoptosis through the CD36 signaling pathway by increasing oxidative stress [37]. CD36 has been reported to be upregulated in the kidney tissue of a nephrotic mouse. When glucose or fatty acid levels rise, the upregulation of CD36 can promote epithelial-mesenchymal transition in renal tubular epithelial cells and apoptosis of podocytes, thereby promoting the occurrence of diabetic nephropathy [36, 38]. Increased CD36 expression in the kidneys of CKD patients leads to renal dysfunction accompanied by systemic abnormalities, including proteinuria, renal lipid accumulation, and glomerular lesions [37, 39]. Recent studies have shown that renal abnormalities are attenuated in CD36-/- mice, suggesting that CD36 plays an important role in the pathogenesis of kidney diseases [33, 37, 38]. The deletion of CD36 in mice largely reduced fatty acid uptake and ectopic renal lipid accumulation and prevented the progression of renal disease. In vitro, silencing CD36 almost abrogated inflammatory cytokine-induced fatty acid uptake, cellular FFA accumulation, and cellular stress. Ox-LDL uptake in renal tubular cells is mainly mediated by CD36 [22, 40]. A recent study found that the CD36-mediated signal pathway leads to proteinuria-induced tubulointerstitial injury [41, 42]. These researches suggest that CD36 can be a promising target for the treatment of renal injury [34].

3.2. Megalin- and Cubilin-Mediated Endocytosis. In addition, the renal proximal tubule retrieves albumin-bound FFA from the filtrate by megalin- and cubilin-mediated albumin endocytosis [31, 43–45]. It has been proposed that the excess of free fatty acids in the proximal tubule may result from the lipid cargo brought by increased filtered albumin, resulting in an increase in the rate of lipid uptake by albumin endocytosis through the receptor megalin and its extracellular binding partner cubulin [31, 43]. The megalin-cubulin complex is considered to be a low-affinity mechanism that operates in a high-capacity endocytic system that can readily account for the uptake of approximately 10 μg/ml of albumin in the tubular filtrate [31]. Albumin is an efficient carrier of fatty acids.
In megalin knockout mice fed with a high-fat diet, the kidney has lesser fatty acid-rich albumin uptake than the HFD-fed control mice [46]. Megalin could also mediate proximal tubular uptake of L-FABP, which may also exert nephrotoxic effects [47].

### 3.3. SLC27 A2- and SR-A-Mediated Lipid Uptake

In addition to CD36, SLC27A1-6 and fatty acid transporter proteins take up fatty acids by mediating their transmembrane movement and capturing NEFAs with CoA synthetases. SLC27 A2 (FATP2) is highly expressed in renal tubules according to the human protein profile. Therefore, it is an important candidate for mediating the uptake of fatty acids in the kidney [4]. In vitro microperfusion and in vitro experiments with NEFA-bound albumin at concentrations mimicking apical proximal tubule exposure during glomerular injury showed remarkably reduced NEFA absorption and palmitate-induced apoptosis in microperfused Slc27a2−/− proximal tubules and Slc27a2+/− or FATP2 shRNA-treated proximal tubule cell lines in comparison to wild-type or scrambled oligonucleotide-treated cells, respectively. Thus, FATP2 is a major apical proximal tubule NEFA transporter that regulates lipoapoptosis and may be a target that can prevent CKD progression [48]. Restoring PPARA signaling through drugs or genetics means to improve FAO or block FA transporter Slc27A2 and help protect mice from renal toxicity [49]. Scavenger receptor A1 (SR-A1), which is highly expressed in macrophages, is capable of taking up oxidized LDL (ox-LDL) and is not regulated by intracellular cholesterol [50–53]. Lipids become oxidized and bound to extracellular matrix proteins under conditions of inflammation. Inflammatory cytokines and growth factors enhance the expression of influx pathways, especially SR-A, and inhibit efflux pathways, resulting in a significant accumulation of intracellular lipids [3]. SR-A is also expressed in low levels on renal tubular epithelium. Both mRNA and protein levels of SR-A were increased in 5/6 nephrectomized CRF rats, which contribute to elevated levels of lipid accumulation in the remnant kidney [54]. Additionally, studies on hypercholesterolemic mice showed that an increase of SR-A+ interstitial cells suggest that SR-A+ may play a role in inflammation and renal fibrogenesis [22].

### 4. Ectopic Lipid Accumulation and Fatty Acid-Induced Renal Toxicity

The toxicity of lipids includes fatty acid toxicity and cholesterol toxicity. In this paper, we focus on the relationship between fatty acid toxicity and CKD [55–58]. Ectopic lipid (renal lipid accumulation at ectopic sites), also known as lipotoxicity, refers to the accumulation of FAs in nonadipose tissue. Kidney biopsy specimens from patients with diabetic nephropathy showed lipid accumulation in the glomeruli and tubulointerstitium compared to the normal control group [59, 60]. One hypothesis is that NEFAs bound to serum albumin pass through the glomerular filtration barrier, promoting toxicity by converting NEFAs into toxic proinflammatory metabolites [61]. Since fatty acids are the preferred energy source for proximal tubular cells, a reduction in fatty acid oxidation in CKD affects renal lipid metabolism...
by disturbing the balance between fatty acid synthesis, uptake, and consumption [35]. As a result, increased intracellular lipid accumulation has a key role in the development of renal disease [35, 38, 62, 63]. Genes associated with FAO are downregulated in the kidneys of mice and humans with CKD. Experiments have confirmed that lipids play a direct role in the initiation and progression of CKD [63–67]. More precisely, ample evidence has shown that ectopic lipids are associated with structural and functional changes in mesangial cells, podocytes, and proximal tubular epithelial cells in the kidneys to induce obesity-related CKD progression [68–70]. It has also been demonstrated that strategies to reduce lipid levels have beneficial effects on kidney health [71, 72] (Figure 2).

4.1. Lipid Accumulation and Glomerular Injury. Palmitate is the predominant circulating saturated FFA and is increased in states of insulin resistance [73]. In an animal model of type 1 diabetes, the increase in sterol regulatory element-binding protein (SREBP) in the renal cortex led to the upregulation of enzymes responsible for FFA synthesis, resulting in high triglyceride content [74]. In animals with a normal serum lipid level but with overexpression of SREBP-1, the renal triglyceride level was elevated and mesangial matrix expansion was increased with proteinuria and glomerulosclerosis [3, 74]. High CD36 expression is associated with an increased FFA uptake by podocytes, together with decreased β-oxidation and the accumulation of intracellular lipids. Accumulated FFAs become trapped in the mitochondrial matrix, resulting in mitochondrial reactive oxygen species (ROS) production, lipid peroxidation, and mitochondrial damage and dysfunction [75]. The unbalanced transport and oxidation of FFAs, with an impaired antioxidant response, impair podocyte structure, finally resulting in glomerulopathy [20]. In conclusion, increased triglyceride synthesis and FA uptake by mesangial cells induce diabetic glomerulopathy [3, 74, 76].

4.2. Lipid Accumulation and Renal Tubular Injury. Large lipid droplets accumulate in proximal tubular cells during the nephrotic syndrome called "lipid nephropathy." Tubular NEFA uptake, as well as glomerular proteinuria, and plasma NEFA concentrations all increased in obesity. Excess NEFAs in albuminuria lead to tubulointerstitial injury [77, 78]. Triglyceride accumulation per se in proximal tubules also stimulates renal gluconeogenesis and increases tubular atrophy and interstitial fibrosis [32]. Toxic lipid metabolites alter the redox environment of cells to a more oxidized state, which then reduces their ability to oxidize NEFAs, resulting in further fat accumulation and insulin resistance [32]. Renal proximal tubule cells are the most energy-demanding cells in the body and oxidize fatty acids to produce ATP; therefore, renal tubular epithelial cells (TECs) critically depend on FAO as their energy source. The extraction of fatty acids from the human kidney is linearly related to the concentration of plasma fatty acids [79]. It has been found that when the expression of key enzymes and regulators of FAO is low, intracellular lipid deposition is high in tubulointerstitial fibrosis [80]. Inhibition of FAO in TECs causes ATP depletion, contributing to apoptosis, dedifferentiation, and intracellular lipid deposition, which induce fibrosis (see Figure 2 for details) [80]. In addition, excessive FAs might affect epithelial cells independently from FAO. Lipotoxicity exists and contributes to epithelial injury by directly activating apoptotic signaling or by indirectly promoting the infiltration of inflammatory cells, which is the main factor for fibrosis [81]. Increasing amounts of NEFAs bound to albumin impair mitochondrial respiration and peroxisome-mediated apoptosis of tubular cells [82]. Purified and endotoxin-free albumin bound to palmitate and nonpurified albumin products had a similar influence on cultured tubule epithelial cells (TECs). It has been reported that albumin-bound FAs activate PPAR-δ and then raise tubular inflammation via proinflammatory metabolites in vivo [83]. Harris et al. confirmed these conclusions and demonstrated that an excess of palmitic acid induces endoplasmic reticulum (ER) stress in the kidney peritubular capillary (PTC) model [84]. Apoptosis and oxidative and ER stress form a proinflammatory environment around the renal PTC [85]. Overall, free long-chain nonesterified saturated fatty acids are toxic when added to cultured cells [4].

5. Therapy

5.1. Diet Therapy and Medication. Several studies have highlighted the effectiveness of dietary and lifestyle interventions and pharmacological strategies in kidney dysfunction [6, 7, 86–89]. Significant improvements in renal function through weight loss have suggested the reversibility upon early intervention, playing a role similar to early diabetic nephropathy [70]. Except for increased physical activity, the reduction of caloric intake is strongly recommended for overweight DKD patients [90, 91]. The negative impact of ox-LDL inducing apoptosis in human cultured podocytes can be effectively suppressed by statins in vitro [92]. Saturated FFAs in the pathogenesis of T2DM are thought to induce podocyte endoplasmic reticulum stress and apoptosis [93, 94]. Podocytes loss is a hallmark of DKD, and these cells are vulnerable to damage from saturated rather than monounsaturated FFAs [94]. Endoplasmic reticulum stress and podocyte cell death could be improved by inducing stearoyl-CoA desaturase [95], which converts saturated FFAs to monounsaturated FFAs and is upgraded in podocytes in biopsy specimens from patients with DKD [19]. Hence, monounsaturated fatty acids were beneficial to DKD. Several studies have demonstrated that circulating polyunsaturated fatty acids have beneficial effects on protecting renal function [96]. Long-chain polyunsaturated omega-3 fatty acids (n-3 PUFAs) (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)), which are obtained mainly from cold water fish, have diverse beneficial effects [97]. It has also been confirmed that renal function improved when individuals were given EPA+DHA at doses equal to two portions of fish per week [96]. N-3 and n-6 PUFAs were found to have a positive influence on DKD outcomes via the attenuation of endothelial dysfunction and inflammation as well as the improved control of dyslipidemia and hypertension [98]. High consumption of n-3 PUFAs and n-6 PUFAs was associated with a decrease and increase risk of CKD, respectively
N-3 PUFAs may have therapeutic potential in ameliorating proteinuria in CKD and decreasing triglycerides and inflammation in dialysis patients. As part of a plant-based diet with low content of SFA, increasing consumption of oil-rich fish may benefit patients with CKD or that have the risk of developing CKD [99]. Furthermore, high n-6 PUFA or low SFA intake has been associated with an increased survival rate in dialysis patients [77, 78]. It has been proposed that improving the quality of dietary fat can ameliorate the clinical risk and outcome of CKD [79]. Of note, the ratio of n-3:n-6 is more important than the PUFA intake and the low n-3:n-6 ratio is detrimental for the health of human beings [80, 81]. The unbalanced n-6/n-3 PUFAs ratio, reaching up to 20:1 in some cases, can affect the onset of many underlying diseases, including CKD [82–84].

5.2. Targeted Therapy. The blocking of CD36-governed cellular processes is a promising strategy for treating obesity-related nephropathy. Several studies have demonstrated that metabolic dysfunction, fibrosis pathways, and proteinuria can be impeded by deficiency or blockade of CD36 [33, 82, 100, 101]. Blocking CD36 on podocytes in vitro resulted in cell function with reduced apoptosis and oxidative stress [37, 102–106]. Therefore, blocking the CD36-dependent pathway is expected to be a therapeutic strategy for a variety of kidney diseases, and novel CD36-targeting peptides have the ability of slowing the progression of CKD [107]. Considering the universal expression and cell-specific effects of CD36, future efforts should include the development of new peptides that target specific sites on the receptor and/or select cell populations to limit the potential for off-target effects and increase the efficacy of targeting CD36 in a variety of renal diseases [107].

Inhibition of the Renin-Angiotensin-Aldosterone System (RAAS) is the basis of the therapy for albuminuria and glomerular filtration. Up until now, very limited clinical trials have been carried out on RAAS inhibitors that primarily target the obese population; however, it is worth noting that the antiproteinuria as well as renoprotective effects of angiotensin-converting enzyme (ACE) inhibition were greater in obese than in nonobese patients [108]. Ox-LDL accumulation in the glomeruli stimulates downstream RAS-mitogen activated protein kinase (MAP kinase) signaling cascade leading to mesangial cell proliferation [109]. RAAS activation mediates fatty acid-induced endoplasmic reticulum stress in cultured human proximal tubule cells (HK2) and in mice fed with a high-fat diet [110]. Treatment with the angiotensin II type 1 receptor blocker valsartan, or renin inhibitor aliskiren, significantly suppressed ER stress both in vitro and in vivo [110, 111].

Peroxisome proliferator-activated receptor-alpha (PPAR-α) is a transcription factor predominantly expressed in

![Figure 2: Ectopic lipid accumulation and fatty acid-induced renal toxicity.}
metabolically active tissues, such as renal PTC, and regulates FAO. Lipid accumulation due to FAO inhibition indirectly contributes to fibrogenesis by accelerating inflammation. Researchers using animal and cell models have revealed that agonists of PPAR-α showed benefits in reversing defects in FAO and ameliorating CKD progression [112]. The PPAR-α/PPAR-γ coactivator-1α (PPARGC1A) ensemble plays a dominating role in the regulation of FAO, which is an available therapeutic target in the future. Fenofibrate (a PPAR-α agonist) could enhance FAO in the kidneys and has shown a positive effect in mouse models of CKD [113]. Fenofibrate could reduce renal oxidative stress, systemic triglyceride levels, proteinuria, and glomerulosclerosis, thereby comprehensively improving renal function in mice fed HFD [114]. Cholesterol efflux through the PPAR-liver X receptor alpha-ABCA1 pathway is damaged in IL-1β-treated mesangial cells; however, such a phenomenon can be reversed by PPAR-α agonists by the activation of the “ABCA1 cholesterol efflux” pathway, producing mesangial cells free of IL-1β-governed intracellular lipid accumulation [113]. The overexpression of proximal tubular epithelial cell-specific PPAR-α in mice sufficiently maintained FAO and conferred protection against ischemia/reperfusion injury (IRI) [115]. Multiple clinical trials have also demonstrated the reduction in albuminuria in patients with diabetes when given fenofibrate treatment [4, 116]. For therapeutic purposes, agonists of PPAR-α were widely applied to impede cisplatin-induced acute kidney injury (AKI), ischemia/reperfusion injury (IRI), and FFA accumulation [117–119]. These observations validated the potential therapeutic uses of PPAR-α agonists [3]. It has been reported that PPAR-γ agonists might also protect against renal injury via their antifibrotic and anti-inflammatory effects [120–122].

The farnesoid X receptor (FXR) is another potent therapeutic target that is highly expressed in the kidney [123]. In mice fed HFD and in age-related kidney disease models, increased renal expression of SREBP-1 plays a key role in kidney lipid accumulation and increases the activity of proinflammatory cytokines [106]. Mice treated with an FXR-activating ligand had lower accumulation of triglycerides by regulating fatty acid synthesis and oxidation, which is related to reduced proteinuria and prevents the loss of podocytes [124, 125]. Studies have shown that in HFD-induced obese mice, an FXR agonist protects the kidneys by downregulating the expression level of SREBP-1 [126]. The treatment of obese mice with the semisynthetic FXR agonist obeticholic acid (OCA) reduced the degree of glomerular sclerosis and tubulointerstitial injury by improving mitochondrial function and promoting FA oxidation, which, in turn, reduced mitochondrial stress and ER stress [126]. In another study, administration of OCA to mice prevented early-stage renal damage and protected the kidney from CKD in the long term [123]. In addition, a recent study on nonalcoholic fatty liver disease has shown that the anti-inflammatory effect of FXR activation was the result of a switch in arachidonic acid metabolism [126]. Pharmacological activation of FXR appears to be safe and represents a valid treatment option for the continuously increasing number of overweight patients with CKD [117, 123].

Similar results were observed for doxercalciferol, which is a typical vitamin D agonist [127]. Pioglitazone also has beneficial effects on albuminuria diabetic and obese patients [68].

6. A Vicious Circle of Lipid Disorders and Kidney Disease

Dyslipidemia accelerates the progression of CKD and subsequently causes secondary abnormalities, in particular, in lipid metabolism [3]. As an example, diabetes-induced hypertriglyceridemia results from multiple processes, including enhanced triglyceride generation, faster de novo synthesis stimulated by hyperinsulinemia in type 2 diabetes mellitus (T2DM), and the defective removal of plasma triglyceride [128]. These lipid abnormalities are closely correlated with the preserved kidney function prevalently in diabetic patients. Notably, nondiabetic patients with CKD have similar symptoms of dyslipidemia [129, 130]. CKD also leads to a decrease in FAO, which might be another mechanism resulting in lipid accumulation. The defective utilization of fatty acids leads to energy consumption causing apoptosis and dedifferentiation, eventually contributing to renal fibrosis and CKD progression [4].

7. Summary

The aim of this paper was to review recent progress in the understanding and uncovering of the micromechanisms of CKD and lipid abnormalities. The key hypothesis we believe is that lipid abnormalities directly cause CKD and thus constitute a vicious cycle. Such a seemingly abnormal relationship was theoretically and experimentally validated by elaborately elucidating lipid intake and accumulation as well as their influence on CKD. For all the phenomena considered, it has hopefully been clearly demonstrated that feasible treatment options and great efforts will contribute to advances in the technological and scientific knowledge required to more efficiently prevent and treat CKD.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Authors’ Contributions

K.P., T.G., Z.G., Q.Z., C.L., and H.F. contributed to the writing of the manuscript; Y.L., Z.G., and J.W. conceived the idea and contributed to funding acquisition. Ke Pei and Ting Gui contributed equally to this work.

Acknowledgments

This work was supported by the “Taishan Scholars” Special Foundation of Shandong Province (No. ts201712042) and the National Natural Science Foundation of China (Nos. 81774242 and 81974566).
References

[1] H. Su, C. Wan, C.-T. Lei et al., “Lipid deposition in kidney diseases: interplay among redox, lipid mediators and renal impairment,” *Antioxidants & Redox Signaling*, vol. 28, no. 10, pp. 1027–1043, 2018.

[2] K. Tsuruya, H. Yoshida, M. Nagata et al., “Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population,” *American Journal of Kidney Diseases*, vol. 66, no. 6, pp. 972–983, 2015.

[3] C. K. Abrass, “Cellular lipid metabolism and the role of lipids in progressive renal disease,” *American Journal of Nephrology*, vol. 24, no. 1, pp. 46–53, 2004.

[4] K. Stadler, I. J. Goldberg, and K. Susztak, “The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease,” *Current Diabetes Reports*, vol. 15, no. 7, p. 40, 2015.

[5] F. Asghari, E. Yuzbashian, P. Mirmiran, and F. Azizi, “Associations of dietary macronutrients with glomerular filtration rate and kidney dysfunction: Tehran lipid and glucose study,” *Journal of Nephrology*, vol. 28, no. 2, pp. 173–180, 2015.

[6] E. Yuzbashian, G. Asghari, P. Mirmiran, and F. Azizi, “Adherence to low-sodium dietary approaches to stop hypertension-style diet may decrease the risk of incident chronic kidney disease among high-risk patients: a secondary prevention in prospective cohort study,” *Nephrology, Dialysis, Transplantation*, vol. 33, no. 7, pp. 1159–1168, 2018.

[7] K. Kalantar-Zadeh, C. M. Rhee, J. Chou et al., “The obesity paradox in kidney disease: how to reconcile it with obesity management,” *Kidney International Reports*, vol. 2, no. 2, pp. 271–281, 2017.

[8] R. Mohebi, A. Simforoosh, M. Tohidi, F. Azizi, and F. Hadaegh, “Obesity paradox and risk of mortality events in chronic kidney disease patients: a decade of follow-up in Tehran lipid and glucose study,” *Journal of Renal Nutrition*, vol. 25, no. 4, pp. 345–350, 2015.

[9] W. Pommer, “Preventive nephrology: the role of obesity in different stages of chronic kidney disease,” *Kidney Diseases*, vol. 4, no. 4, pp. 199–204, 2018.

[10] C. Mayrhofer, S. Krieger, N. Huttery et al., “Alterations in fatty acid utilization and an impaired antioxidant defense mechanism are early events in podocyte injury: a proteomic approach,” *Journal of Biological Chemistry*, vol. 285, no. 11, pp. F575–F585, 2007.

[11] A. Kuniyasu, S. Hayashi, and H. Nakayama, “Adipocytes recognize and degrade oxidized low density lipoprotein,” *Journal of Biological Chemistry*, vol. 268, no. 16, pp. 11811–11816, 1993.

[12] D. Okamura, J. López-Guisa, K. Koelsch, S. Collins, and A. Eddy, “Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury,” *American Journal of Physiology-Renal Physiology*, vol. 293, no. 2, pp. F557–F585, 2007.

[13] A. Kuniyasu, S. Hayashi, and H. Nakayama, “Adipocytes recognize and degrade oxidized low density lipoprotein through CD36,” *Biochemical and Biophysical Research Communications*, vol. 295, no. 2, pp. 319–323, 2002.

[14] M. Fabbri, D. Hijjar, and R. Silverstein, “CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism,” *The Journal of Clinical Investigation*, vol. 108, no. 6, pp. 785–791, 2001.

[15] I. Bobulescu, M. Dube, J. Zhang, P. McTero, and O. Moe, “Effect of renal lipid accumulation on proximal tubule Na’/H’ exchange and ammonium secretion,” *American Journal of Physiology-Renal Physiology*, vol. 294, no. 6, pp. F1315–F1322, 2008.

[16] I. Bobulescu, “Renal lipid metabolism and lipotoxicity,” *Current Opinion in Nephrology and Hypertension*, vol. 19, no. 4, pp. 393–402, 2010.

[17] S. Baranova, A. Bocharov, T. Vishnyakova et al., “CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells,” *Journal of Biological Chemistry*, vol. 285, no. 11, pp. 8492–8506, 2010.
[28] W. Liu, Y. Yin, Z. Zhou, M. He, and Y. Dai, "OxLDL-induced II-1 beta secretion promoting foam cells formation was mainly via CD36 mediated ROS production leading to NLRP3 inflammasome activation," *Inflammation Research*, vol. 63, no. 1, pp. 33–43, 2014.

[29] Z. Lopez-Dee, K. Pidcock, and L. Gutierrez, "Thrombospondin-1: multiple paths to inflammation," *Mediators of Inflammation*, vol. 2011, Article ID 296069, 10 pages, 2011.

[30] W. Stremmel, L. Pohl, A. Ring, and T. Herrmann, "A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids," *Lipids*, vol. 36, no. 9, pp. 981–989, 2001.

[31] H. Birn and E. Christensen, "Renal albumin absorption in physiology and pathology," *Kidney International*, vol. 69, no. 3, pp. 440–449, 2006.

[32] J. M. Weinberg, "Lipotoxicity," *Kidney International*, vol. 70, no. 9, pp. 1560–1566, 2006.

[33] D. M. Okamura, S. Pennathur, K. Pasichnyk et al., "CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD," *Journal of the American Society of Nephrology*, vol. 20, no. 3, pp. 495–505, 2009.

[34] H. Yokoi and M. Yanagita, "Targeting the fatty acid transport protein CD36, a class B scavenger receptor, in the treatment of renal disease," *Kidney International*, vol. 89, no. 4, pp. 740–742, 2016.

[35] H. M. Kang, S. H. Ahn, P. Choi et al., "Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development," *Nature Medicine*, vol. 21, no. 1, pp. 37–46, 2015.

[36] X. Yang, Y. Wu, Q. Li et al., "CD36 promotes podocyte apoptosis by activating the pyrin domain-containing-3 (NLRP3) inflammasome in primary nephrotic syndrome," *Medical Science Monitor*, vol. 24, pp. 6832–6839, 2018.

[37] Y. Su, Q. Chen, K. Ma et al., "Astragaloside IV inhibits palmitate-mediated oxidative stress and fibrosis in human glomerular mesangial cells via downregulation of CD36 expression," *Pharmacological Reports*, vol. 71, no. 2, pp. 319–329, 2019.

[38] K. Susztak, E. Ciccone, P. McCue, K. Sharma, and E. Böttiger, "Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy," *PLoS Medicine*, vol. 2, no. 2, article e43, 2005.

[39] R. J. Baines and N. J. Brunskill, "Tubular toxicity of proteinuria," *Nature Reviews Nephrology*, vol. 7, no. 3, pp. 177–180, 2011.

[40] P. Gutwein, M. S. Abdel-Bakky, K. Doberstein et al., "CXCL16 and oxLDL are induced in the onset of diabetic nephropathy," *Journal of Cellular and Molecular Medicine*, vol. 13, no. 9B, pp. 3809–3825, 2009.

[41] R. Baines, R. Chana, M. Hall, M. Febbraio, D. Kennedy, and N. Brunskill, "CD36 mediates proximal tubular binding and uptake of albumin and is upregulated in proteinuric nephropathies," *American Journal of Physiology. Renal Physiology*, vol. 303, no. 7, pp. F1006–F1014, 2012.

[42] L. Li, J. Yang, W. Lee et al., "Palmitate aggravates proteinuria-induced cell death and inflammation via CD36-inflammasome axis in the proximal tubular cells of obese mice," *American Journal of Physiology Renal Physiology*, vol. 315, no. 6, pp. F1720–F1731, 2018.

[43] M. Gekle, "Renal tubule albumin transport," *Annual Review of Physiology*, vol. 67, pp. 573–594, 2005.

[44] A. A. Pollock and P. Poronnik, "Albumin transport and processing by the proximal tubule: physiology and pathophysiology," *Current Opinion in Nephrology and Hypertension*, vol. 16, no. 4, pp. 359–364, 2007.

[45] S. K. Moestrup and L. B. Nielsen, "The role of the kidney in lipid metabolism," *Current Opinion in Lipidology*, vol. 16, no. 3, pp. 301–306, 2005.

[46] S. Kuwahara, M. Hosojima, R. Kaneko et al., "Megalin-mediated tubuloglomerular alterations in high-fat diet-induced kidney disease," *Journal of the American Society of Nephrology*, vol. 27, no. 7, pp. 1996–2008, 2016.

[47] Y. Oyama, T. Takeda, H. Hama et al., "Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules," *Laboratory Investigation*, vol. 85, no. 4, article BF3700240, pp. 522–531, 2005.

[48] S. Khan, P. D. Cabral, W. P. Schilling et al., "Kidney proximal tubule lipopapoptosis is regulated by fatty acid transporter-2 (FATP2)," *Journal of the American Society of Nephrology*, vol. 29, no. 1, pp. 81–91, 2018.

[49] L. Cheng, M. Ge, Z. Lan et al., "Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity," *Archives of Toxicology*, vol. 92, no. 1, pp. 469–485, 2018.

[50] H. Li, M. Freeman, and P. Libby, "Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines," *Journal of Clinical Investigation*, vol. 95, no. 1, pp. 122–133, 1995.

[51] E. Podrez, M. Febbraio, N. Sheibani et al., "Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species," *Journal of Clinical Investigation*, vol. 105, no. 8, pp. 1095–1108, 2000.

[52] A. C. Li and C. K. Glass, "The macrophage foam cell as a target for therapeutic intervention," *Nature Medicine*, vol. 8, no. 11, pp. 1235–1242, 2002.

[53] J. Han, D. Hajjar, J. Tauras, and A. Nicholson, "Cellular cholesterol regulates expression of the macrophage type B scavenger receptor, CD36," *Journal of Lipid Research*, vol. 40, no. 5, pp. 830–838, 1999.

[54] K. H. Cho, H. J. Kim, V. S. Kamanna, and N. D. Vaziri, "Niacin improves renal lipid metabolism and slows progression in chronic kidney disease," *Biochimica et Biophysica Acta*, vol. 1800, no. 1, pp. 6–15, 2010.

[55] X. Ruan, Z. Varghese, and J. Moorhead, "An update on the lipid nephrotoxicity hypothesis," *Nature Reviews Nephrology*, vol. 5, no. 12, pp. 713–721, 2009.

[56] S. Kume, T. Uzu, S. Araki et al., "Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet," *Journal of the American Society of Nephrology*, vol. 18, no. 10, pp. 2715–2723, 2007.

[57] F. Guebre-Egziabher, P. Alix, L. Koppe et al., "Ectopic lipid accumulation: a potential cause for metabolic disturbances and a contributor to the alteration of kidney function," *Biochimie*, vol. 95, no. 11, pp. 1971–1979, 2013.

[58] Z. Li, J. Woollard, S. Wang et al., "Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation," *American Journal of Physiology-Renal Physiology*, vol. 301, pp. 1078–1087, 2011.

[59] W. Hua, H. Huang, L. Tan et al., "CD36 mediated fatty Acid-Induced Podocyte apoptosis via oxidative stress," *PLoS One*, vol. 10, no. 5, article e0127507, 2015.
[60] M. Herman-Edelstein, P. Scherzer, A. Tobar, M. Levi, and U. Gafer, “Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy,” *Journal of Lipid Research*, vol. 55, no. 3, pp. 561–572, 2014.

[61] M. Thomas and G. Schreiner, “Contribution of proteinuria to progressive renal injury: consequences of tubular uptake of fatty acid bearing albumin,” *American Journal of Nephrology*, vol. 13, no. 5, pp. 385–398, 1993.

[62] A. Declèves, Z. Zollikpli, J. Satriano et al., “Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury,” *Kidney International*, vol. 85, no. 3, pp. 611–623, 2014.

[63] S. Khan, B. Abu Jawdeh, M. Goel et al., “Lipotoxic disruption of NHE1 interaction with PI(4,5)P2 expedites proximal tubule apoptosis,” *The Journal of Clinical Investigation*, vol. 124, no. 3, pp. 1057–1068, 2014.

[64] V. Kamanna, D. D. Roh, and M. A. Kirschbaum, “Hyperlipidemia and kidney disease: concepts derived from histopathology and cell biology of the glomerulus,” *Histology and Histopathology*, vol. 13, no. 1, pp. 169–179, 1998.

[65] P.-H. Lee, H.-Y. Chang, Y.-C. Hsu et al., “Hypertriglyceridemia: an independent risk factor of chronic kidney disease in Taiwanese adults,” *The American Journal of the Medical Sciences*, vol. 338, no. 3, pp. 185–189, 2009.

[66] M. Tszawa, K. Iseki, C. Iseki, S. Oshiro, Y. Iikamiya, and S. Takishita, “Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria,” *Kidney International*, vol. 62, no. 5, pp. 1743–1749, 2002.

[67] C. Kovesdy, J. Anderson, and K. Kalantar-Zadeh, “Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome,” *Journal of the American Society of Nephrology*, vol. 18, no. 1, pp. 304–311, 2007.

[68] A. de Vries, P. Ruggenenti, X. Z. Ruan et al., “Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease,” *The Lancet Diabetes & Endocrinology*, vol. 2, no. 5, pp. 417–426, 2014.

[69] H. Zhao, Y. Sui, J. Guan et al., “Fat redistribution and adipocyte transformation in uninephrectomized rats,” *Kidney International*, vol. 74, no. 4, pp. 467–477, 2008.

[70] H.-L. Zhao, Y. Sui, L. He et al., “Lipid partitioning after uninephrectomy,” *Acta Diabetologica*, vol. 48, no. 4, pp. 317–328, 2011.

[71] J. Moorhead, M. Chan, M. El-Nahas, and Z. Varghese, “Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease,” *The Lancet*, vol. 2, no. 8311, pp. 1309–1311, 1982.

[72] B. L. Kasiske, M. P. O’Donnell, H. Lee, Y. Kim, and W. F. Keane, “Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats,” *Kidney International*, vol. 39, no. 6, pp. 1125–1134, 1991.

[73] L. Groop, A. Ekstrand, and C. Forsblom, “Insulin resistance, hypertension and microalbuminuria in patients with type 2 (noninsulin-dependent) diabetes mellitus,” *Diabetologia*, vol. 36, no. 7, pp. 642–647, 1993.

[74] L. Sun, N. Hailaihel, W. Zhang, T. Rogers, and M. Levi, “Role of sterol regulatory element binding protein-1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus,” *Journal of Biological Chemistry*, vol. 277, no. 21, pp. 18919–18927, 2002.

[75] R. Nosadini and G. Tonolo, “Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes,” *Nutrition, Metabolism and Cardiovascular Diseases*, vol. 21, no. 2, pp. 79–85, 2011.

[76] W. Kean, “The role of lipids in renal disease: future challenges,” *Kidney International*, vol. 57, pp. 27–531, 2003.

[77] X. Huang, P. Stenvinkel, A. R. Qureshi et al., “Essential polyunsaturated fatty acids, inflammation and mortality in dialysis patients,” *Nephrology, Dialysis, Transplantation*, vol. 27, no. 9, pp. 3615–3620, 2012.

[78] X. Huang, P. Stenvinkel, A. Qureshi et al., “Clinical determinants and mortality predictability of stearoyl-CoA desaturase-I activity indices in dialysis patients,” *Journal of Internal Medicine*, vol. 273, no. 3, pp. 263–272, 2013.

[79] X. Huang, P. Sjögren, J. Ärnlov et al., “Serum fatty acid profile, insulin sensitivity and the metabolic syndrome in individuals with chronic kidney disease,” *Journal of Internal Medicine*, vol. 275, no. 1, pp. 71–83, 2014.

[80] J. Dyerberg, H. O. Bang, and N. Hjorne, “Fatty acid composition of the plasma lipids in Greenland Eskimos,” *The American Journal of Clinical Nutrition*, vol. 28, no. 9, pp. 958–966, 1975.

[81] T. Shoji, R. Kakiya, T. Hayashi et al., “Serum n-3 and n-6 polyunsaturated fatty acid profile as an independent predictor of cardiovascular events in hemodialysis patients,” *American Journal of Kidney Diseases*, vol. 62, no. 3, pp. 568–576, 2013.

[82] M. Svensson, J. H. Christensen, J. Solling, and E. B. Schmidt, “The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF,” *American Journal of Kidney Diseases*, vol. 44, no. 1, pp. 77–83, 2004.

[83] T. C. Wong, Y. T. Chen, P. Y. Wu et al., “Ratio of dietary n-6/n-3 polyunsaturated fatty acids independently related to muscle mass decline in hemodialysis patients,” *PLoS One*, vol. 10, no. 10, article e1040402, 2015.

[84] W. S. Harris, W. C. Poston, and C. K. Haddock, “Tissue n-3 and n-6 fatty acids and risk for coronary heart disease events,” *Atherosclerosis*, vol. 193, no. 1, pp. 1–10, 2007.

[85] A. Souza, A. Bocharov, I. Baranova et al., “Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation,” *Kidney International*, vol. 89, no. 4, pp. 809–822, 2016.

[86] A. Susan, L. Katrina, B. Jessica, and M. Anna, “Nutrition prescription to achieve positive outcomes in chronic kidney disease: a systematic review,” *Nutrients*, vol. 6, pp. 416–451, 2014.

[87] A. Levin, B. Hemmelgarn, B. Culleton et al., “Guidelines for the management of chronic kidney disease,” *Canadian Medical Association Journal*, vol. 179, no. 11, pp. 1154–1162, 2008.

[88] Scottish Intercollegiate Guidelines Network, *Diagnosis and Management of Chronic Kidney Disease: A National Clinical Guideline*, Elliott House, Edinburgh, UK, 2008.

[89] D. W. Johnson, E. Atai, M. Chan et al., “KHA-CARI guideline: early chronic kidney disease: detection, prevention and management,” *Nephrology*, vol. 18, no. 5, pp. 340–350, 2013.
s of feno-
rist, and R. Kikkawa,

ion by activating the ABCA1 cholesterol e-

fibrates on renal

as TNF-

B. Cui, H. Maimaitiyiming, Q. Zhou, H. Norman, C. Zhou,

on removal of apoptotic cells during chronic kidney
derived fatty acid balance in kidney health and disease: a review,

of polyunsaturated fatty acid consumption in diabetic

nephropathy,

W. Cui, H. Maimaitiyiming, Q. Zhou, H. Norman, C. Zhou,

interaction of thrombospondin1 and CD36

by activating the phosphatidylinositol 3-kinase/AKT-signaling

pathway,

Journal of the American Society of Nephrology

lipids and advanced oxidation protein products,

important receptors promoting renal tubular injury by

CD36 in chronic kidney disease: novel insights and therapeutic opportunities,

Nature Reviews Nephrology, vol. 13, no. 12, pp. 769–781, 2017.

F. Mallamaci, P. Ruggenenti, A. Perna et al., "ACE inhibition is renoprotective against obese patients with proteinuria," Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1122–1128, 2011.

V. S. Kamanna, B. V. Bassa, and S. H. Ganji, "Low density lipoproteins transactivate EGF receptor: role in mesangial cell proliferation," Life Sciences, vol. 83, no. 17-18, pp. 595–601, 2008.

C. Li, Y. Lin, R. Luo et al., "Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney," American Journal of Physiology-Renal Physiology, vol. 310, no. 5, pp. F351–F363, 2016.

M. Qiu, S. Li, L. Jin et al., "Combination of chymostatin and aliskiren attenuates ER stress induced by lipid overload in kidney tubular cells," Lipids in Health and Disease, vol. 17, no. 1, p. 183, 2018.

D. Portilla, L. Mandel, D. Bar-Sagi, and D. Millington, "Anoxia induces phospholipase A2 activation in rabbit renal proximal tubules," American Journal of Physiology-Renal Physiology, vol. 262, no. 3, pp. F354–F360, 1992.

X. Ruan, J. Moorhead, R. Fernando, D. Wheeler, S. Powis, and Z. Varghese, "PPAR agonists protect mesangial cells from interleukin Ibêta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway," Journal of the American Society of Nephrology, vol. 14, no. 3, pp. 593–600, 2003.

Z. Gai, T. Wang, M. Visentin, G. A. Kullak-Ublick, X. Fu, and Z. Wang, "Lipid accumulation and chronic kidney disease," Nutrients, vol. 11, no. 4, p. 722, 2019.

S. Li, K. Nagothu, V. Desai et al., "Transgenic expression of proximal tubule peroxisome proliferator–activated receptor-a in mice confers protection during acute kidney injury," Kidney International, vol. 76, no. 10, pp. 1049–1062, 2009.

T. Davis, R. Ting, J. Best et al., "Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study," Diabetesologia, vol. 54, no. 2, pp. 280–290, 2011.

K. Takahashi, K. Yamada, K. Hori et al., "Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARa deterioration," Toxicology and Applied Pharmacology, vol. 252, no. 3, pp. 237–249, 2011.

K. Nagothu, R. Bhatt, G. Kaushal, and D. Portilla, "Fibrate prevents cisplatin-induced proximal tubule cell death," Kidney International, vol. 68, no. 6, pp. 2680–2693, 2005.

A. Sivaram, Y. Chatterjee, Y. Hattori et al., "Agonists of peroxisome-proliferator activated receptor-alpha (clofibrate and WY14643) reduce renal ischemia/reperfusion injury in the rat," Medical Science, vol. 8, pp. 352–359, 2002.

K. Ishihiki, M. Haneda, D. Koya, S. Maeda, T. Sugimoto, and R. Kikkawa, "Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-
sensitizing action in diabetic rats,” *Diabetes*, vol. 49, no. 6, pp. 1022–1032, 2000.

[121] B. Guo, D. Koya, M. Isono, T. Sugimoto, A. Kashiwagi, and M. Haneda, “Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells,” *Diabetes*, vol. 53, no. 1, pp. 200–208, 2004.

[122] P. Sarafidis and G. Bakris, “Protection of the kidney by thiazolidinediones: an assessment from bench to bedside,” *Kidney International*, vol. 70, no. 7, pp. 1223–1233, 2006.

[123] Z. Gai, L. Chu, Z. Xu, X. Song, D. Sun, and G. Kullak-Ublick, “Farnesoid X receptor activation protects the kidney from ischemia-reperfusion damage,” *Scientific Reports*, vol. 7, no. 1, p. 9815, 2017.

[124] X. X. Wang, T. Jiang, Y. Shen et al., “Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model,” *Diabetes*, vol. 59, no. 11, pp. 2916–2927, 2010.

[125] X. Wang, T. Jiang, Y. Shen et al., “The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria,” *American Journal of Physiology Renal Physiology*, vol. 297, no. 6, pp. F1587–F1596, 2009.

[126] Z. Gai, T. Gui, C. Hiller, and G. Kullak-Ublick, “Farnesoid X receptor protects against kidney injury in Uninephrectomized Obese Mice,” *Journal of Biological Chemistry*, vol. 291, no. 5, pp. 2397–2411, 2016.

[127] X. Wang, T. Jiang, Y. Shen et al., “Vitamin D receptor agonist doxercalciferol modulates dietary fat-induced renal disease and renal lipid metabolism,” *American Journal of Physiology-Renal Physiology*, vol. 300, pp. 801–810, 2011.

[128] M. Taskinen, M. Adiels, J. Westerbacka et al., “Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 31, no. 9, pp. 2144–2150, 2011.

[129] N. Vaziri, “Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences,” *American Journal of Physiology-Renal Physiology*, vol. 290, pp. 262–272, 2006.

[130] V. Chauhan and M. Vaid, “Dyslipidemia in chronic kidney disease: managing a high-risk combination,” *Postgraduate Medicine*, vol. 121, no. 6, pp. 54–61, 2009.